SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
EDB Investments Pte Ltd.

(Last) (First) (Middle)
20 BIOPOLIS WAY #09-01

(Street)
CENTROS U0 138668

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
02/09/2011
3. Issuer Name and Ticker or Trading Symbol
FLUIDIGM CORP [ FLDM ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Series E Preferred Warrant (Right to Buy) (1) (2) Common Stock 43,853(1)(5) $24.22 D(3)(4)
Series E Preferred Stock (1) (6) Common Stock 1,047,955(1)(5) $0 D(3)(4)
Series D Preferred Stock (7) (7) Common Stock 623,531(5)(7) $0 D(3)(4)
Series C Preferred Stock (7) (7) Common Stock 128,025(5)(7) $0 D(4)(8)
1. Name and Address of Reporting Person*
EDB Investments Pte Ltd.

(Last) (First) (Middle)
20 BIOPOLIS WAY #09-01

(Street)
CENTROS U0 138668

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Biomedical Sciences Investment Fund Pte Ltd.

(Last) (First) (Middle)
20 BIOPOLIS WAY #09-01

(Street)
CENTROS U0 138668

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
SINGAPORE BIO INNOVATIONS PTE LTD

(Last) (First) (Middle)
250, NORTH BRIDGE ROAD #20-02
RAFFLES CITY TOWER

(Street)
SINGAPORE U0 179101

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. Reflects the automatic conversion of each share of Series E Preferred Stock into 1.3 shares of Common Stock to occur upon the closing of the Issuer's initial public offering.
2. Expires immediately prior to the closing of the Issuer's initial public offering.
3. Biomedical Sciences Investment Fund Pte ltd is the record holder of the securities reported on Lines 1, 2 and 3 of Table 2.
4. EDB Investments Pte Ltd, or EDB Investments, is the parent entity of Biomedical Sciences Investment Fund Pte Ltd and Singapore Bio-Innovations Pte Ltd. The Economic Development Board of Singapore, or EDB, is the parent entity of EDB Investments. EDB is a Singapore government entity. EDB Investments, EDB and the Singapore government may be deemed to have shared voting and dispositive power over the shares owned beneficially and of record by Biomedical Sciences Investment Fund Pte Ltd and Singapore Bio-Innovations Pte Ltd. Jeremy Loh, one of the Issuer's directors, is a Vice President (Investments), San Francisco Center for EDB Investments Pte Ltd, Singapore. Dr. Loh disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.
5. Reflects a 1-for-1.73 reverse stock split of the Issuer's outstanding shares effected on February 3, 2011.
6. Each share has no expiration date.
7. Reflects the automatic conversion of each share of Series C Preferred Stock and Series D Preferred Stock into one share of Common Stock to occur upon the closing of the Issuer's initial public offering. Each share has no expiration date.
8. Singapore Bio-Innovations Pte Ltd is the record holder of the securities reported on Line 4 of Table 2.
Matthew McCardell 02/10/2011
Matthew McCardell 02/10/2011
Matthew McCardell 02/10/2011
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.